{"id":"NCT01100112","sponsor":"Bausch Health Americas, Inc.","briefTitle":"(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets","officialTitle":"Multicenter, Open-Label Efficacy and Safety Study of Oral Budesonide-MMX 9mg Extended Release Tablets in Patients With Mild to Moderate, Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2010-07","completion":"2010-08","firstPosted":"2010-04-08","resultsPosted":"2014-06-05","lastUpdate":"2019-11-29"},"enrollment":61,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colitis, Ulcerative"],"interventions":[{"type":"DRUG","name":"Budesonide","otherNames":[]}],"arms":[{"label":"Budesonide","type":"EXPERIMENTAL"}],"summary":"Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are not in remission based on the Ulcerative Colitis Disease Activity Index in study CB-01-02/01 (parent study \\[NCT00679432\\]).","primaryOutcome":{"measure":"The Percentage of Patients Achieving Clinical Remission","timeFrame":"At the end of the 8 week treatment period","effectByArm":[{"arm":"Budesonide","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":15,"countries":["India"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":60},"commonTop":["Blood cortisol decreased","Urinary tract infection","Cushingoid","Diarrhoea","Asthenia"]}}